Results 131 to 140 of about 141,673 (284)

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos   +4 more
wiley   +1 more source

LTB‐TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge   +25 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu   +4 more
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Efficacy of lymph node dissection for duodenal cancer according to the lymph node station

open access: yesAnnals of Gastroenterological Surgery
Background Lymph node metastasis (LNM) is associated with poor prognosis in patients with duodenal cancer (DC). However, the efficacy and optimal extent of lymph node (LN) dissection have not been thoroughly discussed.
Yuya Miura   +7 more
doaj   +1 more source

Intensive Endoscopic Resection for Downstaging of Superficial Non-ampullary Duodenal Epithelial Tumor Burden in Familial Adenomatous Polyposis: A Single-center Retrospective Study on Long-term Clinical Outcome. [PDF]

open access: yesDEN Open
ABSTRACT Background and Study Aims Familial adenomatous polyposis (FAP) is a genetic condition that increases the risk of developing colorectal polyposis and cancer, as well as superficial non‐ampullary duodenal epithelial tumors (SNADETs). In this single‐center retrospective study, we investigated the long‐term clinical outcomes of intensive ...
Kawamura R   +9 more
europepmc   +2 more sources

From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system

open access: yesThe FEBS Journal, EarlyView.
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger   +3 more
wiley   +1 more source

Mechanisms underpinning the progression of nondysplastic Barrett's oesophagus to cancer

open access: yesThe FEBS Journal, EarlyView.
Barrett's oesophagus confers a low but significant cancer risk. The condition is common but we do not have effective biomarkers to identify susceptible patients. We believe that there is no single factor that determines cancer risk and an understanding of the combinations of interactions (via gene expression and natural selection) between the Barrett's
Yannick H. Derwa   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy